Search

Your search keyword '"Honarpour, Narimon"' showing total 6 results
Start Over Author "Honarpour, Narimon" Publisher wiley
6 results on '"Honarpour, Narimon"'

1. The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure ( COSMIC ‐ HF )

Author

Biering‐Sørensen, Tor, primary, Minamisawa, Masatoshi, additional, Liu, Jiankang, additional, Claggett, Brian, additional, Papolos, Alexander I., additional, Felker, G. Michael, additional, McMurray, John J.V., additional, Legg, Jason C., additional, Malik, Fady I., additional, Honarpour, Narimon, additional, Kurtz, Christopher E., additional, Teerlink, John R., additional, and Solomon, Scott D., additional

Published
2021
Full Text
View/download PDF

3. New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

Author

Cowie, Martin R., primary, Filippatos, Gerasimos S., additional, Alonso Garcia, Maria de los Angeles, additional, Anker, Stefan D., additional, Baczynska, Anna, additional, Bloomfield, Daniel M., additional, Borentain, Maria, additional, Bruins Slot, Karsten, additional, Cronin, Maureen, additional, Doevendans, Pieter A., additional, El-Gazayerly, Amany, additional, Gimpelewicz, Claudio, additional, Honarpour, Narimon, additional, Janmohamed, Salim, additional, Janssen, Heidi, additional, Kim, Albert M., additional, Lautsch, Dominik, additional, Laws, Ian, additional, Lefkowitz, Martin, additional, Lopez-Sendon, Jose, additional, Lyon, Alexander R., additional, Malik, Fady I., additional, McMurray, John J.V., additional, Metra, Marco, additional, Figueroa Perez, Santiago, additional, Pfeffer, Marc A., additional, Pocock, Stuart J., additional, Ponikowski, Piotr, additional, Prasad, Krishna, additional, Richard-Lordereau, Isabelle, additional, Roessig, Lothar, additional, Rosano, Giuseppe M.C., additional, Sherman, Warren, additional, Stough, Wendy Gattis, additional, Swedberg, Karl, additional, Tyl, Benoit, additional, Zannad, Faiez, additional, Boulton, Caroline, additional, and De Graeff, Pieter, additional

Published
2017
Full Text
View/download PDF

4. Erratum to “Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency” [Eur J Heart Fail 2016;18:482‐489]

Author

Anker, Stefan D., primary, Schroeder, Stefan, additional, Atar, Dan, additional, Bax, Jeroen J., additional, Ceconi, Claudio, additional, Cowie, Martin R., additional, Crisp, Adam, additional, Dominjon, Fabienne, additional, Ford, Ian, additional, Ghofrani, Hossein‐Ardeschir, additional, Gropper, Savion, additional, Hindricks, Gerhard, additional, Hlatky, Mark A., additional, Holcomb, Richard, additional, Honarpour, Narimon, additional, Jukema, J. Wouter, additional, Kim, Albert M., additional, Kunz, Michael, additional, Lefkowitz, Martin, additional, Floch, Chantal Le, additional, Landmesser, Ulf, additional, McDonagh, Theresa A., additional, McMurray, John J., additional, Merkely, Bela, additional, Packer, Milton, additional, Prasad, Krishna, additional, Revkin, James, additional, Rosano, Giuseppe M.C., additional, Somaratne, Ransi, additional, Stough, Wendy Gattis, additional, Voors, Adriaan A., additional, and Ruschitzka, Frank, additional

Published
2016
Full Text
View/download PDF

5. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency

Author

Anker, Stefan D., primary, Schroeder, Stefan, additional, Atar, Dan, additional, Bax, Jeroen J., additional, Ceconi, Claudio, additional, Cowie, Martin R., additional, Crisp, Adam, additional, Dominjon, Fabienne, additional, Ford, Ian, additional, Ghofrani, Hossein-Ardeschir, additional, Gropper, Savion, additional, Hindricks, Gerhard, additional, Hlatky, Mark A., additional, Holcomb, Richard, additional, Honarpour, Narimon, additional, Jukema, J. Wouter, additional, Kim, Albert M., additional, Kunz, Michael, additional, Lefkowitz, Martin, additional, Le Floch, Chantal, additional, Landmesser, Ulf, additional, McDonagh, Theresa A., additional, McMurray, John J., additional, Merkely, Bela, additional, Packer, Milton, additional, Prasad, Krishna, additional, Revkin, James, additional, Rosano, Giuseppe M.C., additional, Somaratne, Ransi, additional, Stough, Wendy Gattis, additional, Voors, Adriaan A., additional, and Ruschitzka, Frank, additional

Published
2016
Full Text
View/download PDF

6. Association between systolic ejection time and outcomes in heart failure by ejection fraction.

Author

Patel PA, Ambrosy AP, Phelan M, Alenezi F, Chiswell K, Van Dyke MK, Tomfohr J, Honarpour N, and Velazquez EJ

Subjects
Aged, Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, Diabetes Mellitus, Type 2, Female, Humans, Male, Middle Aged, Percutaneous Coronary Intervention, Prognosis, Stroke Volume, Heart Failure epidemiology
Abstract

Aims: Worsening heart failure (HF) is associated with shorter left ventricular systolic ejection time (SET), but there are limited data describing the relationship between SET and clinical outcomes. Thus, the objective was to describe the association between SET and clinical outcomes in an ambulatory HF population irrespective of ejection fraction (EF)., Methods and Results: We identified ambulatory patients with HF with reduced EF (HFrEF) and HF with preserved EF (HFpEF) who had an outpatient transthoracic echocardiogram performed between August 2008 and July 2010 at a tertiary referral centre. Multivariable logistic regression was used to evaluate the association between SET and 1-year outcomes. A total of 545 HF patients (171 HFrEF, 374 HFpEF) met eligibility criteria. Compared with HFpEF, HFrEF patients were younger [median age 60 years (25th-75th percentiles 50-69) vs. 64 years (25th-75th percentiles 53-74], with fewer females (30% vs. 56%) and a similar percentage of African Americans (36% vs. 35%). Median (25th-75th percentiles) EF with HFrEF was 30% (25-35%) and with HFpEF was 54% (48-58%). Median SET was shorter (280 ms vs. 315 ms, P < 0.001), median pre-ejection period was longer (114 ms vs. 89 ms, P < 0.001), and median relaxation time was shorter (78.7 ms vs. 93.3 ms, P < 0.001) among patients with HFrEF vs. HFpEF. Death or HF hospitalization occurred in 26.9% (n = 46) HFrEF and 11.8% (n = 44) HFpEF patients. After adjustment, longer SET was associated with lower odds of the composite of death or HF hospitalization at 1 year among HFrEF but not HFpEF patients., Conclusion: Longer SET is independently associated with improved outcomes among HFrEF patients but not HFpEF patients, supporting a potential role for normalizing SET as a therapeutic strategy with systolic dysfunction., (© 2019 European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results